News: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

57.46USD
24 Dec 2014
Price Change (% chg)

$0.25 (+0.44%)
Prev Close
$57.21
Open
$57.25
Day's High
$57.86
Day's Low
$57.25
Volume
1,060,650
Avg. Vol
2,957,138
52-wk High
$62.20
52-wk Low
$49.24

Search Stocks
Select another date:

Tue, Dec 23 2014

CORRECTED-Connections between drug makers and educators abound

(Corrects second paragraph to say "scholarships funded by Merck, Zoetis, Cargill and others this year.")

Exclusive: Can the blood of Ebola survivors create a cure?

CHICAGO - For months, Vanderbilt University researcher Dr. James Crowe has been desperately seeking access to the blood of U.S. Ebola survivors, hoping to extract the proteins that helped them overcome the deadly virus for use in new, potent drugs. | Video

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

Tetraphase's antibiotic succeeds late-stage trial, shares rise

- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck & Co Inc's ertapenem in a late-stage study.

UPDATE 2-Tetraphase's antibiotic succeeds late-stage trial, shares rise

* Shares rise 17.5 pct in extended trading (Adds details from conference call, analyst quotes)

Tetraphase's antibiotic succeeds in late-stage trial

Dec 17 - Tetraphase Pharmaceuticals Inc said its antibiotic drug to treat complicated intra-abdominal infections was as effective as Merck & co Inc's ertapenem in a late-stage study.

TRLPC: Merck looks for $8B bridge for Cubist acquisition

NEW YORK, Dec 15 - Merck & Co Inc is approaching banks about an $8 billion, 364-day bridge loan that will back the drugmaker's plans to acquire Cubist Pharmaceuticals Inc, sources told Thomson Reuters LPC.

CORRECTED-India caps prices of 52 more "essential" drugs - pricing authority

(Corrects paragraph 4 to say Merck Ltd is a unit of Merck KGaA, not Merck & Co Inc)

UPDATE 2-Ebola vaccine trial halted temporarily after joint pains -Geneva hospital

* Lausanne says safety data "satisfactory" in GSK vaccine trial (Adds statement on GSK Ebola vaccine, new paras 4-7)

UPDATE 2-$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag

* Further funding of up to $90 mln to help vaccine roll-out (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment)

Select another date:
Search Stocks